Archives
- 2018-07
- 2018-10
- 2018-11
- 2019-04
- 2019-05
- 2019-06
- 2019-07
- 2019-08
- 2019-09
- 2019-10
- 2019-11
- 2019-12
- 2020-01
- 2020-02
- 2020-03
- 2020-04
- 2020-05
- 2020-06
- 2020-07
- 2020-08
- 2020-09
- 2020-10
- 2020-11
- 2020-12
- 2021-01
- 2021-02
- 2021-03
- 2021-04
- 2021-05
- 2021-06
- 2021-07
- 2021-08
- 2021-09
- 2021-10
- 2021-11
- 2021-12
- 2022-01
- 2022-02
- 2022-03
- 2022-04
- 2022-05
- 2022-06
- 2022-07
- 2022-08
- 2022-09
- 2022-10
- 2022-11
- 2022-12
- 2023-01
- 2023-02
- 2023-03
- 2023-04
- 2023-05
- 2023-06
- 2023-07
- 2023-08
- 2023-09
- 2023-10
- 2023-11
- 2023-12
- 2024-01
- 2024-02
- 2024-03
- 2024-04
- 2024-05
- 2024-06
- 2024-07
- 2024-08
- 2024-09
- 2024-10
- 2024-11
- 2024-12
- 2025-01
- 2025-02
- 2025-03
-
Cyprodime hydrochloride sale TDG furthermore is inhibited in
2022-04-12
TDG, furthermore, is inhibited in its excision of U on the NCP relative to duplex, though not to the same extent as SMUG1. There is no significant difference between TDGFL and TDG82−308, consistent with a previous report that the N- and C-termini missing from TDG82−308 do not affect the excision of
-
nefiracetam To date glycine receptors have been
2022-04-12
To date, glycine receptors have been found in five distinct transmembrane protein subunits (one β subunit and four α subunit (α1–α4)), combining to form two different types of functional receptors [4], [14], either α homomeric, the immature extrasynaptic glycine receptor subtype, or αβ heteromeric,
-
The standard model of stress
2022-04-12
The standard model of stress postulates the activation of both the sympathoadrenomedullary axis and the hypothalamo-pituitary-adrenocortical axis. Long-term activation of either neuroendocrine axes has been shown to be harmful [12]. Short-term activation of the sympathoadrenomedullary axis is used t
-
Polyunsaturated fatty acids PUFAs represent a class
2022-04-12
Polyunsaturated fatty acids (PUFAs) represent a class of lipids that contain two or more carbon double (unsaturated) bonds (CC) and classified as n-3, n-6 and n-9 fatty acids. PUFAs including n-3 such as docosahexaenoic Cathepsin S inhibitor (DHA), eicosapentaenoic acid (EPA) and n-6 such as arachi
-
The development of immobilization techniques for glucosidase
2022-04-12
The development of immobilization techniques for β-glucosidase offers a potential way to enable its reuse several times [13]. The aim of immobilization is to trap the enzyme within or on the surface of an insoluble material with retention of its catalytic activity [14]. The immobilization strategy a
-
It is widely acknowledged that a significant gap exists betw
2022-04-12
It is widely acknowledged that a significant gap exists between the increasingly detailed knowledge of subcellular mechanisms and the ability to control large-scale anatomy. Radical advances in regenerative medicine require approaches aimed at taming the fundamental complexity of cellular regulation
-
APETx2 From a cell signaling perspective given the
2022-04-12
From a cell signaling perspective, given the importance of agonist-directed signaling and biased agonism, one goal of this research update was to review the known contributions of G protein-dependent versus β-arrestin-dependent signals toward promotion of beneficial functions that FFA4 facilitates.
-
N1-Methylpseudo-UTP Furthermore the immunoassays described i
2022-04-11
Furthermore, the immunoassays described in our study showed excellent concordance of more than 93.33% with the LAg-Avidity EIA (Table 2). Using a panel of samples obtained from HIV-1 seroconverters over the course of up to 602 days post-infection, the gp41 peptide-based MP3 or MP4 assay identified s
-
The most abundant form of Hat p in the nucleus
2022-04-11
The most abundant form of Hat1p in the nucleus is apt to be in the form of the NuB4 complex [96]. In the context of Phenformin assembly, the function of the NuB4 complex may be similar to that ascribed for the cytoplasmic HAT1 complex. That is, the NuB4 complex may be involved in directing newly sy
-
br Dual acting HR antagonists While the present
2022-04-11
Dual-acting HR antagonists While the present medicinal chemistry efforts are mainly focused on selective ligands targeting GPCRs, and particularly on H1R, H3R and H4R selective antagonists/agonists, there were and, also, still are several efforts to develop dual acting H1R/H2R, H1R/H3R and H3R/H4
-
Mizoribine receptor Upon LPS stimulation ERK and STAT signal
2022-04-11
Upon LPS stimulation, ERK and STAT3 signaling pathways were activated in a time-dependent manner, and the phosphorylation of Y705 occurred later than that of S727 (Supplementary Fig. S5B). STAT3 is known to be phosphorylated on serine 727 (S727) by the mitogen-activated protein (MAP) kinase pathway
-
tgf beta receptor inhibitor RS testing has been extensively
2022-04-11
RS testing has been extensively validated in patients with early stage, ER+, HER2− patients. TAILORx, a randomized controlled trial to evaluate the role of adjuvant chemotherapy by RS, found no recurrence or survival benefit to the addition of chemotherapy to endocrine therapy in patients with inter
-
br STAR Methods br Acknowledgments We thank Prof Y
2022-04-11
STAR★Methods Acknowledgments We thank Prof. Y. Tomari at the University of Tokyo for experimental advice and K. Hanada for technical assistance. This research was supported by Grants-in-Aid for Scientific Research on Innovative Areas “Nascent Chain Biology” (JP15H01548 and JP17H05677 to T.I. a
-
The isoenzyme hGSTP is an attractive drug target due to
2022-04-11
The isoenzyme hGSTP1-1 is an attractive drug target due to its high levels of disease association (target validation) and druggability (target tractability) properties [5,6,[17], [18], [19], [20], [21]]. hGSTP1-1 functions as a homodimer protein [18]. Each monomer has two domains, an α/β domain (N-t
-
Pharmacologic approaches of inhibiting GSNOR activity have r
2022-04-11
Pharmacologic approaches of inhibiting GSNOR activity have reached the point of clinical development with the recent announcement of the first cystic fibrosis patients treated with the first-in-class GSNOR inhibitor, N6022 (N30 Pharmaceuticals). Clinical development is ongoing for other indications
15752 records 432/1051 page Previous Next First page 上5页 431432433434435 下5页 Last page